VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The findings, which validate the platform's ability to distinguish between breast cancer and healthy cells, represent a significant step forward in the development of safer and more effective cancer therapies.
The company reported that BiTAC-ADCs achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components. This approach aims to reduce the off-target effects commonly associated with traditional antibody-drug conjugates (ADCs), which can limit their therapeutic window and cause harmful side effects in patients.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
The BiTAC-ADC platform is based on a novel mechanism that uses two separately administered components: a tumor-targeting antibody and a systemically inactive precursor drug. Once the antibody binds to the tumor, the precursor is activated locally, releasing the therapeutic agent specifically at the cancer site. This design could potentially expand the range of solid tumors treatable with ADCs while reducing systemic toxicity.
Industry analysts note that the ability to achieve tumor-restricted activation is a critical unmet need in oncology. Traditional ADCs often suffer from premature drug release and off-target toxicity, limiting their effectiveness and patient tolerability. VERAXA's approach could address these limitations, potentially improving outcomes for patients with breast cancer and other solid tumors.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
